BRAF and colorectal carcinoma: Specifically, in CRC samples without the BRAF mutation, HAMLET treatment led to a 39% reduction in the non-phosphorylating (V0) respiration rate (from 12 ± 2.646 to 7.3 ± 3.215 pmolO/s/mg dry weight) and a 33.3% decrease in the state 3 (VADP) respiration rate (from 13 ± 1 to 8.67 ± 3.786 pmolO/s/mg dry weight).